Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia

NCT02791191 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02791191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02791191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Terminated
Start date
June 16, 2016
Completion date
July 2, 2018
Enrollment
316 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease